Biodexa Pharmaceuticals Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	-	-	0.38	0.7	0.58	0.34	Upgrade
Revenue Growth (YoY)	-	-	-45.49%	20.93%	68.51%	-49.11%	Upgrade
Cost of Revenue	5.44	5.44	4.07	5.11	4.65	6.07	Upgrade
Gross Profit	-5.44	-5.44	-3.69	-4.41	-4.08	-5.73	Upgrade
Selling, General & Admin	4.14	3.79	3.03	4.54	2.95	4.96	Upgrade
Research & Development	-0.52	-	-	-	-	-	Upgrade
Other Operating Expenses	-0.06	-0.03	-0.01	-0.02	-0.02	-0.01	Upgrade
Operating Expenses	3.56	3.76	3.02	4.52	2.92	4.95	Upgrade
Operating Income	-8.99	-9.2	-6.7	-8.93	-7	-10.67	Upgrade
Interest Expense	-0.25	-0.17	-0.04	-0.05	-0.04	-0.03	Upgrade
Interest & Investment Income	0.17	0.17	0.08	0.03	-	0	Upgrade
Other Non Operating Income (Expenses)	2.56	3.22	0.49	0.47	0.94	-0.4	Upgrade
EBT Excluding Unusual Items	-6.52	-5.98	-6.18	-8.49	-6.11	-11.1	Upgrade
Impairment of Goodwill	-	-	-	-	-	-2.29	Upgrade
Asset Writedown	-	-	-	-	-	-10.08	Upgrade
Other Unusual Items	-	-	-1.31	-	-	-	Upgrade
Pretax Income	-6.52	-5.98	-7.49	-8.49	-6.11	-23.47	Upgrade
Income Tax Expense	-0.29	-0.25	-0.41	-0.83	-0.65	-1.28	Upgrade
Earnings From Continuing Operations	-6.23	-5.73	-7.08	-7.66	-5.46	-22.19	Upgrade
Net Income	-6.23	-5.73	-7.08	-7.66	-5.46	-22.19	Upgrade
Net Income to Common	-6.23	-5.73	-7.08	-7.66	-5.46	-22.19	Upgrade
Shares Outstanding (Basic)	0	0	-	-	-	-	Upgrade
Shares Outstanding (Diluted)	0	0	-	-	-	-	Upgrade
EPS (Basic)	-48.60	-115.67	-	-	-	-	Upgrade
EPS (Diluted)	-48.60	-115.67	-	-	-	-	Upgrade
Free Cash Flow	-10.77	-12.27	-6.85	-7.11	-6.33	-9.51	Upgrade
Free Cash Flow Per Share	-84.04	-247.74	-	-	-	-	Upgrade
Operating Margin	-	-	-1759.58%	-1277.83%	-1210.73%	-3111.08%	Upgrade
Profit Margin	-	-	-1858.01%	-1095.28%	-944.64%	-6469.10%	Upgrade
Free Cash Flow Margin	-	-	-1798.42%	-1017.17%	-1094.81%	-2772.60%	Upgrade
EBITDA	-8.87	-9.08	-6.56	-8.76	-6.79	-9.57	Upgrade
D&A For EBITDA	0.12	0.12	0.14	0.17	0.21	1.1	Upgrade
EBIT	-8.99	-9.2	-6.7	-8.93	-7	-10.67	Upgrade
Revenue as Reported	-	-	-	-	-	0.34	Upgrade

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q